<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368836</url>
  </required_header>
  <id_info>
    <org_study_id>433</org_study_id>
    <secondary_id>R42HL086316-01</secondary_id>
    <nct_id>NCT00368836</nct_id>
  </id_info>
  <brief_title>Breath Analysis Technique to Diagnose Pulmonary Embolism</brief_title>
  <official_title>Expired CO2/O2 Analysis to Diagnose Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>WFD Ventures Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually&#xD;
      caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs,&#xD;
      but it is not always accurate for individuals who have recently undergone surgery or who have&#xD;
      inflammatory-provoking diseases. The purpose of this study is to evaluate the effectiveness&#xD;
      of the Carboximeter, a new PE diagnostic device that measures carbon dioxide (CO2) and oxygen&#xD;
      (O2) output, in individuals at risk for developing PEs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PE is the second leading cause of sudden, unexpected death in the United States. In 90% of&#xD;
      the cases, it is caused by deep vein thrombosis: a blood clot forms in a vein, travels&#xD;
      through the bloodstream, and lodges in the lungs. PE symptoms vary, and can include cough,&#xD;
      shortness of breath, chest pain, rapid breathing, or increased heart rate. Some medical&#xD;
      procedures and diseases activate inflammation and blood coagulation, thereby making&#xD;
      individuals more vulnerable to PE. Surgery, kidney dialysis, cancer, connective tissue&#xD;
      diseases, infectious diseases, and being over 70 years old put individuals at increased risk&#xD;
      for developing PEs. A common screening test for PE is the D-dimer blood test, which measures&#xD;
      the level of a specific protein that is released following a PE. This test, however, has&#xD;
      proven to be an unreliable diagnostic tool for individuals who are at high risk for PE. A&#xD;
      more reliable diagnostic tool is needed. The Carboximeter is a new device that measures the&#xD;
      ratio of CO2/O2 pressure in an individual's expired breath. By monitoring these components,&#xD;
      researchers may be able to accurately diagnose PEs in high risk individuals. The purpose of&#xD;
      this study is to evaluate the effectiveness of the Carboximeter at diagnosing PE in&#xD;
      individuals at risk for developing PEs.&#xD;
&#xD;
      This study will be conducted in two phases. In Phase I, CO2/O2 ratio and D-dimer levels will&#xD;
      be measured prior to and following orthopedic or cancer-related surgery in 100 individuals at&#xD;
      risk for developing PEs. In Phase II, the same measurements will be carried out on 350 high&#xD;
      risk individuals who are experiencing PE symptoms. These individuals will also undergo&#xD;
      computed tomography (CT) angiography and venography, in which blood flow will be visualized&#xD;
      using x-rays. A follow-up evaluation will occur 30 days later. If any participant from Phase&#xD;
      I or II experiences a PE or a medical condition that affects their lungs, such as asthma or&#xD;
      chronic obstructive pulmonary disease (COPD), researchers may schedule a follow-up evaluation&#xD;
      to obtain repeat measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement</measure>
    <time_frame>Pre-op measurement: the morning of surgery. Post-op measurement: the latter of postoperative day 3 or hospital discharge</time_frame>
    <description>Median postoperative change in end tidal CO2/O2 ratio calculated as 100% * [(postoperative-preoperative)/(preoperative)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Probability of Pulmonary Embolism Diagnosis by D-dimer Alone vs. D-Dimer Plus CO2/O2 for Pulmonary Embolism Diagnosed by CT Scan.</measure>
    <time_frame>Measured at 45 days</time_frame>
    <description>D-dimer &gt; 499 ng/ml, etCO2/O2 &lt; 0.28, Pulmonary Embolism diagnosed by CT scan</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>BreathScreen PE + D-dimer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BreathScreen PE</intervention_name>
    <description>One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level</description>
    <arm_group_label>BreathScreen PE + D-dimer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase I Inclusion Criteria:&#xD;
&#xD;
          -  Experienced or is scheduled for at least one of the following:&#xD;
&#xD;
               1. Hip or knee replacement surgery&#xD;
&#xD;
               2. Hip or acetabular fracture surgery&#xD;
&#xD;
               3. Pelvic fracture&#xD;
&#xD;
               4. Decompression for spinal stenosis surgery&#xD;
&#xD;
               5. Scoliosis corrective surgery&#xD;
&#xD;
               6. Craniotomy surgery for brain tumor&#xD;
&#xD;
               7. Surgery for any of the following cancers: bladder, colon (including caecum and&#xD;
                  rectum), kidney, ovary, pancreas, or uterus&#xD;
&#xD;
        Phase I Exclusion Criteria:&#xD;
&#xD;
          -  Currently undergoing treatment for PE or has received treatment for PE in the 4 weeks&#xD;
             prior to study entry&#xD;
&#xD;
          -  Hospitalized for fewer than 2 days&#xD;
&#xD;
          -  Anatomic abnormality that would prevent use of a mouthpiece&#xD;
&#xD;
          -  Living situation that makes follow-up difficult (e.g., homeless, incarcerated)&#xD;
&#xD;
        Phase II Inclusion Criteria:&#xD;
&#xD;
          -  Clinical suspicion of PE with signs or symptom suggestive of PE within 24 hours of&#xD;
             presentation and at least one risk factor for PE, as defined under the criteria as&#xD;
             outlined in this protocol&#xD;
&#xD;
          -  CTA of pulmonary arteries ordered by clinical care providers&#xD;
&#xD;
          -  18 years or older or an emancipated 17 year old&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Phase II Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamic instability, including patients with a systolic blood pressure less than&#xD;
             90 mm Hg&#xD;
&#xD;
          -  Severe respiratory distress or the inability to breathe room air without the sensation&#xD;
             of severe dyspnea&#xD;
&#xD;
          -  Pulse oximetry reading that declines more than 10% when exogenous oxygen is&#xD;
             discontinued with accompanying worsening or new dyspnea&#xD;
&#xD;
          -  Intubated&#xD;
&#xD;
          -  Cannot breathe through the mouth owing to anatomic, physical or mental limitation&#xD;
&#xD;
          -  No fixed address, no telephone number, are from out of town or have other reason to&#xD;
             suspect difficulty with follow-up&#xD;
&#xD;
          -  Incarceration&#xD;
&#xD;
          -  Known active tuberculosis&#xD;
&#xD;
          -  Prior PE or DVT with history of medical noncompliance with oral anticoagulation&#xD;
             therapy based upon a history of unplanned subtherapeutic INR measurements (less than&#xD;
             1.5)&#xD;
&#xD;
          -  Active PE within previous 6 months and currently under treatment with anticoagulation&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Disallowed medications: treatment with any fibrinolytic agent within 48 hours prior to&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jefferey A. Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kline JA, Hogg M. Measurement of expired carbon dioxide, oxygen and volume in conjunction with pretest probability estimation as a method to diagnose and exclude pulmonary venous thromboembolism. Clin Physiol Funct Imaging. 2006 Jul;26(4):212-9.</citation>
    <PMID>16836693</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>Capnography</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Arthroplasty</keyword>
  <keyword>D-dimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase I - subjects scheduled for elective surgery enrolled from January 2006-May 2006. Phase II - Hospitalized as well as Emergency Department patients were enrolled from February, 2007 to April, 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BreathScreen PE</title>
          <description>BreathScreen PE and D-Dimer collected on subjects scheduled for elective surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unable to collect blood and/or breath</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I Pre-op/Post-op</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125">The phases consisted of unique subjects. Those enrolled in Phase I did not carry over to Phase II.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase II</title>
          <description>Symptomatic population undergoing testing for pulmonary embolism. Blood samples were used to obtain D-dimer levels and breath samples were used to generate the BreathScreen PE CO2/O2 ratio.</description>
        </group>
        <group group_id="B2">
          <title>Phase I</title>
          <description>Pre-op/Post op subjects undergoing surgery. Blood and breath samples were collected before and after surgery. Blood samples were used to obtain D-dimer levels and breath samples were used to generate the BreathScreen PE CO2/O2 ratio.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="15.9"/>
                    <measurement group_id="B2" value="62" spread="12"/>
                    <measurement group_id="B3" value="56.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement</title>
        <description>Median postoperative change in end tidal CO2/O2 ratio calculated as 100% * [(postoperative-preoperative)/(preoperative)]</description>
        <time_frame>Pre-op measurement: the morning of surgery. Post-op measurement: the latter of postoperative day 3 or hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BreathScreen PE</title>
            <description>BreathScreen PE and D-Dimer collected on subjects scheduled for elective surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement</title>
          <description>Median postoperative change in end tidal CO2/O2 ratio calculated as 100% * [(postoperative-preoperative)/(preoperative)]</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>end tidal CO2/O2 ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-13" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" lower_limit="40" upper_limit="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II: Probability of Pulmonary Embolism Diagnosis by D-dimer Alone vs. D-Dimer Plus CO2/O2 for Pulmonary Embolism Diagnosed by CT Scan.</title>
        <description>D-dimer &gt; 499 ng/ml, etCO2/O2 &lt; 0.28, Pulmonary Embolism diagnosed by CT scan</description>
        <time_frame>Measured at 45 days</time_frame>
        <population>Completed patients minus unrecoverable data (4) and indeterminate CT scan (2).</population>
        <group_list>
          <group group_id="O1">
            <title>CO2/O2 Plus D-dimer</title>
            <description>Probability of pulmonary embolism diagnosis by CO2/O2 collected with the BreathScreen PE plus D-dimer measurement as compared to D-dimer alone. D-dimer &gt; 499 ng/ml, etCO2/O2 &lt; 0.28, Pulmonary Embolism diagnosed by CT scan</description>
          </group>
          <group group_id="O2">
            <title>D-dimer</title>
            <description>Probability of pulmonary embolism diagnosis by D-dimer alone as compared to D-dimer plus CO2/O2 measured with the BreathScren PE. D-dimer &gt; 499 ng/ml, etCO2/O2 &lt; 0.28, Pulmonary Embolism diagnosed by CT scan</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Probability of Pulmonary Embolism Diagnosis by D-dimer Alone vs. D-Dimer Plus CO2/O2 for Pulmonary Embolism Diagnosed by CT Scan.</title>
          <description>D-dimer &gt; 499 ng/ml, etCO2/O2 &lt; 0.28, Pulmonary Embolism diagnosed by CT scan</description>
          <population>Completed patients minus unrecoverable data (4) and indeterminate CT scan (2).</population>
          <units>probability of PE diagnosis</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32"/>
                    <measurement group_id="O2" value="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>45 days</time_frame>
      <desc>348 of the 350 enrolled subjects were assessed for device-related adverse events because two participants did not have study data collection initiated: one participant requested to withdraw and another participant was designated as a screen fail.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase II</title>
          <description>Phase II: symptomatic subjects undergoing testing for PE</description>
        </group>
        <group group_id="E2">
          <title>Phase I</title>
          <description>Pre-op/Post op: subjects undergoing surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Kline</name_or_title>
      <organization>Carolinas Medical Center</organization>
      <phone>704-355-3181</phone>
      <email>jkline@carolinas.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

